Ayman Battisha

Dr. Ayman Battisha

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2019 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
OSOmar Sheikh
Omar Sheikh
AHAnthony G. Vande Hei
Anthony G. Vande Hei
ABAyman Battisha
Ayman Battisha
THTarek Hammad
Tarek Hammad
SPSon Pham
Son Pham
RCRobert Chilton
Robert Chilton
Heart disease continues to affect health outcomes globally, accounting for a quarter of all deaths in the United States. Despite the improvement in the development and implementation of guideline-directed medical therapy, the risk of adverse cardiac events remains substantially high. Historically, it has been debated whether omega-3 polyunsaturated fatty acids provide clinical benefit in cardiac disease. The recently published REDUCE-IT trial demonstrated a statistically significant absolute risk reduction of 4.8% in its primary endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) with the use of icosapent ethyl, which is a highly purified eicosapentaenoic acid (EPA) ethyl ester. However, the mechanism of action of omega-3 fatty acids is not commonly discussed. Moreover, the use of EPA was not without risk, as the incidence of atrial fibrillation was increased along with a trend towards increased bleeding risk. Thus, our aim is to help explain the function of purified EPA ethyl ester, especially at the molecular level, which will ultimately lead to a better understanding of their clinically observable effects.

1 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SSSidra Shah
Sidra Shah
VCVipanpreet Chahil
Vipanpreet Chahil
ABAyman Battisha
Ayman Battisha
SHSyed Haq
Syed Haq
Dinesh K. KalraDinesh K. Kalra
Dinesh K. Kalra
Atrial fibrillation (AF) in the postoperative phase is a manifestation of numerous factors, including surgical stress, anesthetic effects, and underlying cardiovascular conditions. The resultant cardiac hyperactivity can induce new onset or exacerbate existing AF. A common phenomenon, postoperative atrial fibrillation (POAF) affects nearly 40% of patients and is associated with longer hospitalization stays, and increased mortality, heart failure, stroke, and healthcare costs. Areas of controversy in POAF include whether to anticoagulate patients who have short-lived POAF, especially given their higher bleeding risk in the postoperative period, and the identification of patients who would benefit the most from preventive drug therapy for POAF. This review discusses the pathophysiology and management of POAF, and strategies to reduce its occurrence.

7 May 2021 in Current Cardiology Reviews
Verified
Journal Article
Open access
PDF file
KDKarim Doughem
Karim Doughem
ABAyman Battisha
Ayman Battisha
OSOmar Sheikh
Omar Sheikh
LKLakshmi Konduru
Lakshmi Konduru
BMBader Madoukh
Bader Madoukh
SSShakil Shaikh
Shakil Shaikh
: Hydralazine, an arterial vasodilator, is a widely used medication for the management of hypertension and heart failure, especially for patients who cannot tolerate the use of ACEIs or ARBs. It is generally well-tolerated and has a safe profile in pregnancy. However, hydralazine can induce immune-mediated side effects, such as hydralazine-induced lupus and less commonly hydralazine- induced ANCA vasculitis. The latter most commonly affects the kidneys with or without other organ involvement. There are several cases reported in the literature of hydralazine-induced ANCA associated vasculitis (AAV) that have pulmonary manifestations, also known as hydralazine- induced pulmonary-renal syndrome (PRS), a condition with a high risk of mortality. We are reporting a case of Hydralazine-induced ANCA associated glomerulonephritis with severe diffuse alveolar hemorrhage (DAH). In addition, we will review the current literature and discuss the importance of prompt diagnosis and early management to decrease mortality and morbidity associated with this serious condition.

30 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ABAyman Battisha
Ayman Battisha
AKAmrit Kahlon
Amrit Kahlon
Dinesh K. KalraDinesh K. Kalra
Dinesh K. Kalra
Background/Objectives: Sleep-disordered breathing (SDB), historically referred to as “sleep apnea syndrome”, particularly obstructive sleep apnea (OSA), is an independent risk factor for hypertension (HTN), stroke, heart failure, arrhythmias, and other cardiovascular disorders. Despite the well-established link between OSA and HTN and its high occurrence in cardiovascular disorders, the focus on the complex OSA–HTN axis is often overlooked or inadequately managed, which might explain the lack of notable improvements in cardiovascular outcomes for this patient population. Understanding the complex relationship between OSA and HTN is crucial due to its significant implications for clinical practice and public health. Methods: Using an expanded list of relevant MeSH terms, including “sleep-disordered breathing” and “sleep apnea syndrome”, and following the PRISMA model, peer-reviewed articles were systematically selected. Studies published from January 2000 through December 2024 were identified and screened based on predefined inclusion and exclusion criteria. Results: This review emphasizes both OSA’s independent and interaction effects on cardiovascular health and outcomes across different populations. It identifies key factors mediating the association between OSA and HTN. Conclusions: Multimodal management, including continuous positive airway pressure and lifestyle modification, is essential for treating hypertension related to OSA. Effective management of the OSA–HTN relationship is vital to improving cardiovascular outcomes.

20 June 2020 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
ABAyman Battisha
Ayman Battisha
KSKhalid Sawalha
Khalid Sawalha
AAAhmed M. Altibi
Ahmed M. Altibi
BMBader Madoukh
Bader Madoukh
MAMohammad Al-Akchar
Mohammad Al-Akchar
BPBrijesh Patel
Brijesh Patel

19 May 2020 in Current Cardiology Reviews
Verified
Journal Article
Open access
PDF file
ABAyman Battisha
Ayman Battisha
BMBader Madoukh
Bader Madoukh
OSOmar Sheikh
Omar Sheikh
AAAhmed Altibi
Ahmed Altibi
SSShakil Sheikh
Shakil Sheikh
MAMohammed Al-Sadawif
Mohammed Al-Sadawif
Coronary Artery Fistulas (CAF) are inappropriate connections between a coronary artery and a major vessel or a cardiac chamber. These fistulas may or may not present with symptoms, but they need to be detected as early as possible in order to decide the most appropriate treatment methodology (i.e. surgery vs. conservative management). We report the case of a 67-year-old female with no modifiable cardiovascular risk factors who had an unwitnessed sudden death at home during her ongoing evaluation of a fistula detected incidentally between the Left Anterior Descending Artery (LAD) and the Pulmonary Artery (PA). This case highlights that early diagnosis and treatment of symptomatic CAF are crucial to minimize the risk of sudden cardiac death. Although the symptomatic fistula of LAD to PA has been reported in the literature multiple times, it has been rarely reported that this fistula can result in sudden cardiac death.